Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis
Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.
1. A compound of formula I
wherein
Z is an oxadiazole;
X is N;
R 1 and R 2 are chosen independently from —(C 1 -C 8 )hydrocarbyl, OH, —O(C 1 -C 8 )hydrocarbyl, halogen, nitro, (C 1 -C 3 )alkylamino, (C 1 -C 3 )dialkylamino, (C 1 -C 3 )acylamino, (C 1 -C 3 )alkylsulfonyl, (C 1 -C 3 )alkylthio, (C 1 -C 3 )haloalkyl, (C 1 -C 3 )haloalkoxy, (C 1 -C 3 )haloalkylthio, —COOH, —C(═O)O(C 1 -C 3 )alkyl, —B(OR 3 ) 2 , and —BF 3 K; and
R 3 is H or (C 1 -C 8 )hydrocarbyl; or (OR 3 ) 2 , taken together with the boron to which they are attached form a dioxaborolane or dioxaborinane ring optionally substituted with from one to four (C 1 -C 8 )hydrocarbyl.
2. A compound according to claim 1 wherein Z is
3. A compound according to claim 1 wherein Z is
4. A compound according to claim 1 wherein R 1 is chosen from halogen, —COOH, —C(═O)O(C 1 -C 3 )alkyl, —B(OR 3 ) 2 , and —BF 3 K.
5. A compound according to claim 1 wherein R 2 is chosen from halogen, (C 1 -C 3 )haloalkyl, —O(C 1 -C 3 )alkyl, —B(OR 3 ) 2 , and —BF 3 K.
6. A compound according to claim 1 wherein R 1 is chosen from bromine, COOEt, and —BF 3 K.
7. A compound according to claim 1 wherein R 2 is chosen from bromine, CF 3 and —OCH 3 .
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 .
9. A method for inhibiting the interaction of homeodomain interacting protein kinase 2 (HIPK2) with Smad3, said method comprising bringing HIPK2 into contact with a compound of claim 1 .
10. A method for inhibiting Smad3 activation, said method comprising bringing Smad3 into contact with a compound of claim 1 .
11. The method according to claim 9 wherein the method is an in vitro method.
12. The method according to claim 9 wherein the method is an in vivo method.
13. The method according to claim 10 wherein the method is an vitro method.
14. The method according to claim 10 wherein the method is an in vivo method.
15. A method for treating a fibrotic disease comprising administering a compound of claim 1 to a subject suffering from a fibrotic disease.
16. A method according to claim 15 wherein said disease is renal fibrosis.
17. A compound of formula II
wherein
X is chosen from N and CH;
R 1 and R 2 are chosen independently from —(C 1 -C 8 )hydrocarbyl, OH, —O(C 1 -C 8 )hydrocarbyl, halogen, nitro, (C 1 -C 3 )alkylamino, (C 1 -C 3 )dialkylamino, (C 1 -C 3 )acylamino, (C 1 -C 3 )alkylsulfonyl, (C 1 -C 3 )alkylthio , (C 1 -C 3 )haloalkyl, (C 1 -C 3 )haloalkoxy, (C 1 -C 3 )haloalkylthio, —COON, —C(═O)O(C 1 -C 3 )alkyl, —B(OR 3 ) 2 , and —BF3K; and
R 3 is H or (C 1 -C 8 )hydrocarbyl; or (OR 3 ) 2 , taken together with the boron to which they are attached form a dioxaborolane or dioxaborinane ring optionally substituted with from one to four (C 1 -C 8 )hydrocarbyl,
with the provision that when X is CH and R 2 is —O(C 1 -C 3 )alkyl, then R 1 is not (C 1 -C 3 )alkyl.
18. A method for inhibiting the interaction of homeodomain interacting protein kinase 2 (HIPK2) with Smad3, said method comprising bringing HIPK2 into contact with a compound of claim 17 .
19. A method for inhibiting Smad3 activation, said method comprising bringing Smad3 into contact with a compound of claim 17 .
20. A method for treating a fibrotic disease comprising administering a compound of claim 17 to a subject suffering from a fibrotic disease.
21. A method according to claim 20 wherein said disease is renal fibrosis.